Press Release
<< Back
Verastem Oncology Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
As described in the proxy materials for the annual meeting previously distributed, you are entitled to participate in the annual meeting if you were a stockholder of record as of on
To gain access to the meeting, you must go to the meeting website at www.virtualshareholdermeeting.com/VSTM2020 (website will be active prior to the meeting) and enter the 16-digit control number provided on the proxy card, voting instruction form or notice regarding the availability of proxy materials previously received. The virtual meeting website will contain participation instructions.
Whether or not planning to attend the annual meeting, stockholders are encouraged to vote in advance of the annual meeting by one of the methods described in the proxy materials. Stockholders who have previously voted do not need to take any further action. The proxy card and voting instruction form included with the previously distributed proxy materials will not be updated to reflect the change from an in-person meeting to a virtual-only meeting and may continue to be used to vote shares in connection with the annual meeting.
For further information, please refer to the Company’s proxy statement and notice regarding the availability of proxy materials, filed with the
About Verastem Oncology
Our first FDA approved product is available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).
For more information, please visit www.verastem.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005900/en/
Verastem Oncology:
Investors:
Vice President, Investor Relations & Finance
+1 781-469-1546
jdoyle@verastem.com
Media:
Corporate Communications
+1 781-292-4205
lbuffington@verastem.com
Source: